Long-term efficacy of rasagiline in early Parkinson's disease.

Abstract

This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N = 398) and subsequent open-label extension. Patients were followed for up to 6.5 years with a mean of 3.5 +/- 2.1 years. After 12 months, additional PD medications were added as required. Of patients remaining in the trial at 2 years, 46% were maintained on rasagiline monotherapy. The majority of patients received a dopamine agonist prior to levodopa as the first additional dopaminergic agent. Analysis using a Kaplan-Meier method indicated that by 5.4 years only 25% of patients progressed to Hoehn & Yahr stage III. Rasagiline was well tolerated, with 11.3% of patients (45/398) withdrawing because of an adverse event. Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.

DOI: 10.3109/00207451003778744

Cite this paper

@article{Lew2010LongtermEO, title={Long-term efficacy of rasagiline in early Parkinson's disease.}, author={Mark F. Lew and Robert A. Hauser and Howard I. Hurtig and William G. Ondo and Joanne M Wojcieszek and Tamar Goren and Cheryl J. Fitzer-Attas}, journal={The International journal of neuroscience}, year={2010}, volume={120 6}, pages={404-8} }